New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Medline Inc. (&#34;Medline&#34; or the &#34;Company&#34;)

<p>New York, New York--(Newsfile Corp. - July 24, 2026) - <a href="https://api.newsfilecorp.com/redirect/vEGVVFDwOQ">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MDLN">MDLN</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/JkO22uAKmX">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/Gz5ooCyPje"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."</p><p>Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.</p><p>According to a June 3, 2026 <i>Reuters </i>article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months."  Further, the <i>Reuters </i>article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/Q2RPPs71kP">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/mjXBBc4yja">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/kXRkkCVJN2">https://www.kaplanfox.com/case/medline-inc-class-action-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/306383_6c8416c01484c9ed_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/B5Gjjcp85j">https://www.newsfilecorp.com/release/306383</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/306383/197" alt="" /></p>

MDLN

Kaplan Fox Encourages Investors of Medline Inc. (MDLN) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

Medline under FDA scrutiny, facing securities probe by Kaplan Fox

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Medline Inc. (&amp;#34;Medline&amp;#34; or the &amp;#34;Company&amp;#34;)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Following an FDA warning letter for significant CGMP violations, Kaplan Fox launched a securities investigation into Medline. MDLN shares dropped about 7% to $33.19 on June 2, 2026, signaling investor concern over potential enforcement costs and litigation. The outcome could hinge on further FDA actions, quality controls, and any eventual settlements or disclosures.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>FDA warns Medline on CGMP violations. Kaplan Fox investigates potential securities violations.</li><li>MDLN stock fell 7.16% to $33.19 on June 2, 2026.</li><li>Reuters notes the latest FDA action is the second in two months.</li><li>Kaplan Fox highlights investor contact for potential claims.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Medline Inc. (MDLN)</strong>: Subject of FDA warning letter and potential securities investigation; near-term price risk.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Plaintiffs&#039; law firm leading or soliciting investors for potential claims; may indicate litigation risk.</li><li><strong>FDA (N/A)</strong>: Issued CGMP warning letter to Medline; regulatory risk and potential penalties.</li><li><strong>Reuters (N/A)</strong>: Reporting the second FDA action in two months; corroborates regulatory risk.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits due to ongoing securities investigation and FDA enforcement actions affecting Medline&#039;s regulatory and litigation risk profile.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA CGMP violations and second FDA action raise enforcement risk for MDLN.</li><li>MDLN shares declined about 7% on June 2, 2026 to $33.19.</li><li>Reuters confirms second FDA action in two months, signaling ongoing quality issues.</li><li>Kaplan Fox securities investigation could add legal costs and settlement risk.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>FDA warning letter dated May 28, 2026 citing significant CGMP violations at Medline.</li><li>MDLN closed at $33.19 on June 2, 2026, down $2.56 (-7.16%).</li><li>Reuters (June 3, 2026) states the FDA action is the second in two months; microbial contamination and inadequate cleaning cited.</li><li>Kaplan Fox &amp; Kilsheimer LLP is examining potential securities violations against Medline.</li><li>MDLN NASDAQ ticker.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term MDLN downside risk driven by regulatory and legal headlines; monitor for settlement or additional enforcement actions within 1–3 quarters.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - July 24, 2026) - <a href="https://api.newsfilecorp.com/redirect/vEGVVFDwOQ">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MDLN">MDLN</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/JkO22uAKmX">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/Gz5ooCyPje"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."</p><p>Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.</p><p>According to a June 3, 2026 <i>Reuters </i>article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months."  Further, the <i>Reuters </i>article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/Q2RPPs71kP">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/mjXBBc4yja">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/kXRkkCVJN2">https://www.kaplanfox.com/case/medline-inc-class-action-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/306383_6c8416c01484c9ed_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/B5Gjjcp85j">https://www.newsfilecorp.com/release/306383</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/306383/197" alt="" /></p>

Following an FDA warning letter for significant CGMP violations, Kaplan Fox launched a securities investigation into Medline. MDLN shares dropped about 7% to $33.19 on June 2, 2026, signaling investor concern over potential enforcement costs and litigation. The outcome could hinge on further FDA actions, quality controls, and any eventual settlements or disclosures.

News insight

Kaplan Fox Encourages Investors of Medline Inc. (MDLN) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

AI summary

Sentiment rationale

Key facts

Legal